

**CUE BIOPHARMA, INC.**  
40 Guest Street  
Boston, Massachusetts 02135

May 24, 2023

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance, Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Tyler Howes

Re: Cue Biopharma, Inc.  
Registration Statement on Form S-3  
Filed May 9, 2023  
File No. 333-271786  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. (the "Registrant") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-271786), so that it may become effective at 4:30 p.m. Eastern time on May 26, 2023, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the Staff.

Very truly yours,

**CUE BIOPHARMA, INC.**

By: /s/ Kerri-Ann Millar  
Name: Kerri-Ann Millar  
Title: Chief Financial Officer